Vertex, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher David Young
- Full Time Employees
- 2,100
- Sector
- Technology
- Industry
- Software - Application
- Address
- 2301 Renaissance Boulevard King of Prussia PA United States of America 19406
- IPO Date
- Jul 29, 2020
- CIK
- 0001806837
- Website
- vertexinc.com
- Similar Companies
- Business
- Vertex, Inc. is a technology company primarily engaged in providing tax compliance, tax automation, and related software solutions. The company offers a comprehensive suite of products and services including indirect tax software for managing sales and use tax, value-added tax (VAT), goods and services tax (GST), and other transactional taxes globally; automated tax determination software; tax data management solutions; cloud-based and on-premise tax compliance software; and integrated tax engines for enterprise resource planning (ERP) systems. Vertex’s product portfolio supports a range of industries including retail, manufacturing, financial services, and telecommunications, serving customers worldwide. The company also provides implementation, consulting, and support services to help businesses comply with evolving tax regulations. Founded in 1978 and headquartered in King of Prussia, Pennsylvania, Vertex operates internationally with offices and clients across North America, Europe, and Asia. Recently, Vertex has expanded its capabilities through strategic partnerships and new product launches aimed at enhancing its global tax compliance automation offerings. In the past 1-2 years, the company has focused on advancing its cloud-based tax solutions to better address digital tax complexities and cross-border tax compliance challenges. Vertex continues to invest in technology upgrades and integrations to support multinational corporations’ growing needs, positioning itself as a leader in the tax technology industry. These developments reflect Vertex’s commitment to innovation and broadening its market reach, underscoring its role in delivering advanced tax software solutions to help businesses navigate increasingly complex global tax landscapes. The company leverages its proprietary tax engine and extensive tax content database to deliver precise and scalable tax management solutions. Vertex is recognized for its strong customer support and technology-driven approach, targeting large enterprises and mid-market companies needing comprehensive tax automation and compliance tools. This dynamic business environment and Vertex’s expansions highlight the company’s strategic focus on maintaining leadership in the evolving tax technology sector through continuous product enhancement and global operational growth.
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)
Vertex Report: Rising Sales Tax Rates Signal a New Era of Tax Volatility
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
3 Reasons Why Growth Investors Shouldn't Overlook Vertex (VERX)
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday
Vertex Analysts Lower Their Forecasts Following Q2 Results
Vertex Expands Leadership Team to Power the Next Chapter of Growth
Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story
Vertex, Inc. (VERX) Q2 2026 Earnings Call Transcript
Vertex Q2 Earnings Call Highlights
Vertex Pharmaceuticals Q2 Earnings Call Highlights
Compared to Estimates, Vertex (VERX) Q2 Earnings: A Look at Key Metrics
Vertex (VERX) Q2 Earnings and Revenues Top Estimates
Vertex Raises 2026 Guidance, But Shares Fall For One Key Reason
Vertex raises annual revenue forecast on cystic fibrosis drugs strength
Vertex Announces Second Quarter 2026 Financial Results
Vertex Reports Second Quarter 2026 Financial Results
New Vertex Research Signals a Turning Point for Indirect Tax and Compliance: The Rise of Decision-to-Defense
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?